Sorafenib

[SDL] Sorafenib Tablet 200 mg

[MSHL] Sorafenib Tablet 200 mg

1. For cancer treatment.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

04/01/2022 Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma

The Ministry of Health’s Drug Advisory Committee has recommended:

• Sorafenib 200 mg tablet; and

• Lenvatinib 4 mg and 10 mg capsules

for treating advanced unresectable hepatocellular carcinoma in patients with adequate liver function as assessed by the Child-Pugh scoring system.

Subsidy status

[R] Sorafenib 200 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) and lenvatinib 4 mg and 10 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication when used according to HSA-recommended dosing regimens.

[R] SDL subsidy for sorafenib will be implemented from 4 January 2022, while MAF assistance for lenvatinib will be implemented from 1 September 2022.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.

04/01/2022 Lenvatinib and sorafenib for treating differentiated thyroid cancer

The Ministry of Health’s Drug Advisory Committee has recommended:

• Sorafenib 200 mg tablet; and

• Lenvatinib 4 mg and 10 mg capsules

for treating locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

Subsidy status

[R] Sorafenib 200 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.

[R] Lenvatinib 4 mg and 10 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration